Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 2
2006 2
2007 1
2008 1
2009 2
2010 4
2011 6
2012 3
2013 2
2014 3
2015 1
2016 3
2017 3
2018 3
2019 5
2020 4
2021 5
2022 7
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for milan vosmik
Search for Milan Hvostik instead (1 results)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D; KEYNOTE-048 Investigators. Burtness B, et al. Lancet. 2019 Nov 23;394(10212):1915-1928. doi: 10.1016/S0140-6736(19)32591-7. Epub 2019 Nov 1. Lancet. 2019. PMID: 31679945 Clinical Trial.
Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer.
Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, Mendez G, Feliciano J, Motoyama S, Lièvre A, Uronis H, Elimova E, Grootscholten C, Geboes K, Zafar S, Snow S, Ko AH, Feeney K, Schenker M, Kocon P, Zhang J, Zhu L, Lei M, Singh P, Kondo K, Cleary JM, Moehler M; CheckMate 577 Investigators. Kelly RJ, et al. N Engl J Med. 2021 Apr 1;384(13):1191-1203. doi: 10.1056/NEJMoa2032125. N Engl J Med. 2021. PMID: 33789008 Clinical Trial.
Non-Genomic Hallmarks of Aging-The Review.
Holmannova D, Borsky P, Parova H, Stverakova T, Vosmik M, Hruska L, Fiala Z, Borska L. Holmannova D, et al. Among authors: vosmik m. Int J Mol Sci. 2023 Oct 23;24(20):15468. doi: 10.3390/ijms242015468. Int J Mol Sci. 2023. PMID: 37895144 Free PMC article. Review.
Special Techniques of Adjuvant Breast Carcinoma Radiotherapy.
Kolářová I, Melichar B, Vaňásek J, Sirák I, Petera J, Horáčková K, Pohanková D, Šinkorová Z, Hošek O, Vošmik M. Kolářová I, et al. Among authors: vosmik m. Cancers (Basel). 2022 Dec 31;15(1):298. doi: 10.3390/cancers15010298. Cancers (Basel). 2022. PMID: 36612294 Free PMC article. Review.
Cardiotoxicity of radiation therapy in esophageal cancer.
Vošmik M, Hodek M, Buka D, Sýkorová P, Grepl J, Paluska P, Paulíková S, Sirák I. Vošmik M, et al. Rep Pract Oncol Radiother. 2020 May-Jun;25(3):318-322. doi: 10.1016/j.rpor.2020.02.005. Epub 2020 Feb 25. Rep Pract Oncol Radiother. 2020. PMID: 32194352 Free PMC article. Review.
Technological advances in radiotherapy for esophageal cancer.
Vosmik M, Petera J, Sirak I, Hodek M, Paluska P, Dolezal J, Kopacova M. Vosmik M, et al. World J Gastroenterol. 2010 Nov 28;16(44):5555-64. doi: 10.3748/wjg.v16.i44.5555. World J Gastroenterol. 2010. PMID: 21105188 Free PMC article. Review.
The Role of Adjuvant Radiotherapy in the Treatment of Breast Cancer.
Kolářová I, Melichar B, Sirák I, Vaňásek J, Petera J, Horáčková K, Pohanková D, Ďatelinka F, Šinkorová Z, Vošmik M. Kolářová I, et al. Among authors: vosmik m. Curr Oncol. 2024 Feb 24;31(3):1207-1220. doi: 10.3390/curroncol31030090. Curr Oncol. 2024. PMID: 38534923 Free PMC article. Review.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators. Machiels JP, et al. Lancet Oncol. 2024 Mar 29:S1470-2045(24)00100-1. doi: 10.1016/S1470-2045(24)00100-1. Online ahead of print. Lancet Oncol. 2024. PMID: 38561010
57 results